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Glomerular filtration rate determination by creatinine and 
cystatin-C in patients with acute pyelonephritis 
 
Abstract 
Background: Measurement of glomerular filtration rate (GFR) and monitoring of it in any 
patient on nephrotoxic drugs is very important. Recently, cystatin C (cys-C) has been 
introduced as a better marker for determining and monitoring renal function than 
creatinine especially in a mild decrease of GFR. This study was done to assess the change 
of GFR measurement based on serum Cys-C and creatinine and their comparison in 
children with acute pyelonephritis on amikacin. 
Methods: All children with acute pyelonephritis who were admitted in Nephrology ward 
were enrolled in this study. Serum creatinine, serum cys-C and the GFR calculation based 
on them were measured in patients on the day of admission (day zero) and then on days 3 
and 7 after the start of treatment with amikacin and p-value less than 0.05 was considered 
significant. 
Results: Among the 70 children, 61 patients were females and the others were males. 
Mean age was 42.66±41.53 months. Estimated GFR based on creatinine on day 0 (before 
amikacin administration), 3 and 7 were 72.41±20.89 ml/min/1.73 m
2
, 78.42±21.15 
ml/min/1.73 m
2
 and 80.5±22.43 ml/min/1.73 m
2
, respectively. Moreover, GFR based on 
cys-C during these days were 116.23±58.9 ml/min/1.73 m
2
, 116.49±53.31 ml/min/1.73 m
2
 
and 108.37±51.02 ml/min/1.73 m
2
, respectively (p<0.05). 
Conclusions: According to this study, decrease of GFR calculation based on Cys-C was 
seen and estimated GFR was not changed according to creatinine. So, we recommend the 
use of cys-C for the monitoring of renal function in any patient treated with nephrotoxic 
drugs such as amikacin. 
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Renal function is determined by glomerular filtration rate (GFR). Measurement of 
GFR by inulin is a gold standard method. Of course clearance of iohexol is a good method 
for GFR calculation (1). The calculation of GFR by these methods was limited by need of 
high specialized equipment and personnel and also was very expensive. So, the 
measurement of GFR by these materials is used only for researchers (2, 3). In practice, the 
most common method for calculation of GFR is creatinine clearance. Because creatinine is 
an endogenous substance and its measurement is available and low-cost. Creatinine is 
produced via metabolism of the muscles. The main excretion route of creatinine is 
glomerular filtration. Besides, the serum level of creatinine could be affected by tubular 
secretion, sex, age, hepatic disorder, malnutrition and muscle mass (4-6). Recently an 
endogenous marker for estimation of GFR is cystatin C (cys-C). It is a low molecular 
weight protein and reabsorbed and catabolized by the proximal tubules. It is removed from 
the circulation by glomerular filtration. 
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GFR estimation by Cys-C is not influenced by age, 
gender, inflammation, muscle mass and other variables that 
can have effect on serum creatinine concentration. Cys-C 
seems to be a more accurate marker for drug dosage 
adjustment during medication, especially in a mild decrease 
of GFR in children (2, 7-12). 
Aminoglycoside antibiotics are used for treatment of 
many infections, especially gram-negative bacteria and can 
be used in children with pyelonephritis (13-15). The main 
route of excretion of aminoglycosides is the kidneys. 
Aminoglycosides are transferred from plasma into the urine 
by glomerular filtration. Thus, accurate kidney function 
monitoring during the consumption of these drugs is 
necessary. There is a risk of renal nephrotoxicity during the 
use of aminoglycoside. The risk of toxicity is influenced by 
underlying renal disease, dose of drug, duration of use, and 
the patient's age (16-18). 
This study was done in pediatric patients with 
pyelonephritis that were treated with amikacin and its effect 
on renal function was compared by GFR estimation between 
the clearance of creatinine and Cys-C. 
 
 
Methods 
A total of 70 children (61 girls and 9 boys) with acute 
pyelonephritis were enrolled in the study and their age was 
between 2 months to 14 years old (42.66±41.53 months). 
Pyelonephritis was diagnosed with fever, positive urine 
culture and pyuria in the urine analysis. All patients were 
admitted in the Nephrology ward of the Amirkola Childrens 
Hospital, Babol (north of Iran). According to our previous 
study, the most sensitive parenteral drug for treatment of 
UTI was amikacin (19). 
 So in this study, all patients with diagnosis of 
pyelonephritis were treated with amikacin(19). All patients 
were treated with a dose of 5mg/kg Amikacin intravenously 
every 8 hours for 7 days. Initial renal function was normal in 
all patients.  
All patients with positive history of increased creatinine 
or kidney disease were excluded from the study. For every 
patient, serum creatinine and Cys-C were measured before 
the amikacin administration (day 0) and on days 3 and 7 
after the start of treatment. GFR was calculated based on 
these indicators during the treatment period. Creatinine 
clearance was calculated according to the Schwartz equation 
(4). Cys-C clearance was calculated according to Filler 
formula (20). Patients were divided into two groups 
according to their age (patients younger than 2 years and 
those older than 2 years of age). Statistical analysis was 
performed using the SPSS 17 statistical software. Also, 
paired t-test, repeated measures ANOVA and the Pearson 
correlation coefficient were used. A p<0.05 was considered 
statistically significant. 
 
 
Results 
Among the 70 patients, 61 (87.1%) were females and 
(12.9%) were males. Mean age was 42.66±41.53 months. 
Thirty eight (54.28%) patients were less than 2 years old and 
32 (45.71%) patients were more than 2 years. The height of 
patients ranged from 50 cm to 143 cm (88.56±25.82 cm). 
Serum level of blood urea nitrogen (BUN), creatinine and 
Cys-C were measured on the admission day or zero  (before 
amikacin administration), days 3 and day 7 after the 
initiation of treatment. Patient's BUN on days 0, 3 and 7 
were 9.22±2.43 mg/dl, 8.97±2.53 mg/dl and 9.31±2.76 
mg/dl, respectively. According to table 1, serum creatinine 
and Cys-C levels were 0.46±0.09 mg/dl and 0.90±0.27 mg/l 
on day 7, respectively. 
Creatinine clearance (GFR) during the amikacin 
treatment, according to the Schwartz formula was 
96.37±27.04 ml/min/1.73m² on day 7. Also, estimated GFR 
based on Cys-C on day 7 was 108.37±51.02 ml/min/1.73m² 
(p<0.05) (table 1). 
According to the age, the patients were divided into two 
groups: patients less than 2 years and those older than 2 
years of age. Hence, in the group aged under 2 years, 
creatinine concentration in serum on days 0, 3 and 7 was 
0.44±0.07 mg/dl, 0.41±0.06 mg/dl and 0.41±0.5 mg/dl and 
Cys-C was 0.98±0.28 mg/dl, 0.96±0.26 mg/dl and 1.01±0.23 
mg/dl on these days, respectively. In this group GFR 
estimation based on creatinine on day 7 was 80.34±23.75 
ml/min/1.73m² and GFR calculation based on Cys-C was 
88.84±36.30 ml/min/1.73m². (p>0.05) (table 2).  
In children more than 2 years old, creatinine 
concentration in serum on days 0, 3 and 7 was 0.58±0.10 
mg/dl, 0.54±0.08 mg/dl and 0.52±0.08 mg/dl and Cys-C was 
0.74±0.27 mg/dl, 0.72±0.24 mg/dl and 0.77±0.27 mg/dl, 
respectively. GFR estimation based on creatinine on day 7 
was 115.40±16.31 ml/min/1.73m² and GFR calculation 
based on Cys-C was 131.57±56.56 ml/min/1.73m² on day 7 
(p<0.05) (table 2). 
 Caspian J Intern Med 2018; 9(3):290-295  
292                               Sorkhi H, et al. 
Table 1. Mean, standard deviation and range of serum Bun level, creatinine, Cystatin C, GFR based on creatinine and GFR 
based on Cystatin C in children with pyelonephritis treated with Amikacin 
 
GFR based on 
cystatin C 
(ml/min/1.73 m²) 
Serum 
Cystatin C 
(mg/l) 
GFR* based on 
Creatinine 
(ml/min/1.73 m²) 
Serum Creatinine 
(mg/dl) 
Serum BUN 
(mg/dl) 
Day and variation 
116.23 ± 58.90 0.87  ± 0.30 72.41 ± 20.89 0.62 ± 0.13 9.22 ± 2.43 Mean ± SD 0 
36.70-360.40 0.352-1.718 38.63-141.46 0.31-1.09 4-14 Range 
116.49 ± 53.31 0.85 ± 0.28 78.42 ± 21.15 0.58 ± 0.11 8.97± 2.53 Mean ± SD 3 
40.40-272.80 0.345-1.607 37.35-139.14 0.31-0.95 5-17 Range 
108.37 ± 51.02 0.90 ± 0.27 80.50 ± 22.43 0.57 ± 0.11 9.31 ± 2.76 Mean ± SD 7 
39.40-310.90 0.390-1.634 37.35-144.47 0.36-0.82 5-14.7 Range 
*Glomerular filtration rate 
 
Table 2.  Mean, standard deviation and range of serum creatinine, Cystatin C, GFR based on creatinine and GFR based on 
Cystatin C in children younger and older than 2 years with pyelonephritis treated with Amikacin 
 
 Day and variation Serum Creatinine 
(mg/dl) 
GFR based on 
Creatinine 
(ml/min/1.73 m²) 
Serum Cystatin C 
(mg/l) 
GFR based on 
cystatin C 
(ml/min/1.73 m²) 
Younger 
than 2 
years 
0 Mean ± SD 0.44±0.07 74.14 ± 23.04 0.98 ± 0.28 93.26 ± 39.16 
Range 0.25-0.63 38.63-132.62 0.42-1.71 36.70-200.30 
3 Mean ± SD 0.41± 0.06 78.99 ± 23.10 0.96 ± 0.26 97.26 ± 45.72 
Range 0.25-0.56 37.35-132.62 0.42-1.60 40.40-218.80 
7 Mean ± SD 0.41± 0.05 80.34 ± 23.75 1.01 ± 0.23 88.84 ± 36.30 
Range 0.29-0.57 37.35-120.37 0.54-1.52 43.60-193.90 
Older 
than 2 
years 
0 Mean ± SD 0.58 ± 0.10 104.21±  15.56 143.50 ± 66.92 0.74 ± 0.27 
Range 0.36-0.88 78.68-141.21 54.10-216.40 0.35-1.31 
3 Mean ± SD 0.54 ± 0.08 111.66 ± 15.69 139.32 ± 53.28 0.72 ± 0.24 
Range 0.33-0.77 72.35-139.14 68.00-211.20 0.34-1.11 
7 Mean ± SD 0.52 ± 0.08 115.40 ± 16.31 131.57 ± 56.56 0.77 ± 0.27 
Range 0.36-0.66 78.68-144.47 39.40-218.90 0.38-1.63 
 
Discussion 
According to this study, during the 1-week treatment 
with amikacin in children with acute pyelonephritis, serum 
creatinine and calculating GFR did not significantly 
changed. But, the GFR that was calculated by Cys-C 
changed and decreased during the 1- week treatment with 
amikacin (p<0.05).  
In clinical practice, GFR based on creatinine calculated 
with Schwartz formula is used. Furthermore, this GFR 
calculation may be overestimated in comparison to the gold 
standard method (clearance of inulin). As a consequence, we 
must use a better marker that is endogenous, non-expensive 
and non-affected by many factors such as age, drugs and so 
on. These factors affect GFR calculation with creatinine. 
Cys-C is a protease inhibitor that is responsible for the 
intracellular catabolism produced by all nucleated cells. It is 
completely filtered from the glomerulus and reabsorbed and 
metabolized by the tubules. Cys-C is independent of 
inflammatory process in the body, muscle mass, age, sex and 
nutritional status and does not cross the placenta. It is used 
calculating GFR in adults since 1985 by Simonsen (12, 21-
24). There are some studies to compare GFR calculation 
based on creatinine and Cys-C. Although there were no 
studies on children with UTI (urinary tract infection) and on 
amikacin Tsujita study was done on 73 patients with kidney 
transplant and mild to moderate impaired GFR and 
compared calculated GFR based on Cys-C and creatinine 
with inulin. This study showed that Cys-C can determine 
GFR more accurately than creatinine clearance in these 
patients (25). Besides, calculating GFR based on Cys-C in 
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adult patient with chronic kidney disease (CKD) had better 
accuracy than creatinine to determine GFR (26). The same 
result was shown by Linen in children with impaired renal 
function (7).  
As mentioned above, GFR based on Cys-C has better 
accuracy than creatinine and may replace the calculation of 
GFR instead of creatinine. But there are limited studies to 
evaluate drug nephrotoxicity and compare the change and 
probability decrease of GFR by Cys-C. Conseqently, further 
studies need to be done. Halacova reported 71 cystic fibrosis 
patients who were treated with amikacin. GFR in patients 
was determined for several days. Finally, he showed Cys-C 
is more appropriate to determine the change of GFR than 
creatinine (17). In another study of 130 patients treated with 
amikacin, tobramycin, vancomycin and gentamicin, reported 
that Cys-C is more valuable than creatinine for calculation of 
GFR and drug dose adjustment (27). In our study, a GFR 
calculation based on creatinine did not change during the use 
of amikacin in children with pyelonephritis after 7 days. But, 
according to the calculation of GFR by Cys-C in these 
patients, GFR statistically decreased.  
Although this reduction of GFR may not be clinically 
important But, a more serious decrease of GFR may occur 
with increased duration of treatment or higher dose of drug. 
This study showed there is a risk of change of GFR even in a 
short period use of the drug, especially in children treated for 
acute pyelonephritis. There are some studies that showed 
different results. O'Riordan’s study concluded that serum 
Cys-C does not have any advantages over creatinine in 
elderly people in predicting digoxin clearance. But only 18 
volunteers completed the study. Definitely, the sample size 
was small (28). Schuck et al. also showed no considerable 
difference between serum Cr, CysC and GFR based on 
Cockroft-Gault formula for evaluating GFR and adjusting 
dosage of drug in adults (29).  
Naturally, there are some aspects that may be considered 
for the estimation of GFR based on Cys-C. For example, 
there is not any study about the effect of tubular dysfunction 
at serum level of Cys-C and also on GFR. The serum level of 
Cys-C may be affected by CRP, thyroid dysfunction and 
corticosteroid consumption. Moreover, compared to GFR 
with creatinine and Cys-C in children may be problematic 
and in compatible. There are some reports about the effect of 
age, sex and weight on serum level of Cys-C (30-35). 
According to the risk of amikacin nephrotoxicity in children 
with low ages, the patients were divided into two groups: 
under and above the age of 2 years, respectively. In both 
groups, serum Cr and GFR based on Cr had no significant 
change during treatment. But, serum Cys-C increased and as 
a result, GFR measured with Cys-C decreased during 
treatment period. The changes were more considerable in the 
group of children over 2 years than the group of children 
under 2 years. 
In conclusion, Cys-C is a more reliable method than 
creatinine for the evaluation of amikacin nephrotoxicity in 
children with acute pyelonephritis even in a short period of 
time. Consequently, we recommend the use of Cys-C in any 
children who was treated with amikacin for evaluation of 
drug nephrotoxicity. 
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